Work

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.4597

Authors: John Sfakianos, Dimitar Shishkov, Nikola V. Mihaylov, Alexandre Khuskivadze, Pencho Genov, Vasyl Terzi, Max Kates, Willliam C. Huang, Michael J. Louie, Sunil Raju, Brent Burger, Andrew Meads, Sandip M. Prasad, The ENVISION Study Group

Institutions: Icahn School of Medicine at Mount Sinai, National Institute of Emergency Medicine "Pirogov", Military Medical Academy, Johns Hopkins University, NYU Langone Health, UroGen Pharma Ltd. (United States), Morristown Medical Center, Atlantic Health System

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: UroGen Pharma

OpenAlex ID: W4410822169

Cites:

Cited by:

Related to: 10